Journal
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
Volume 25, Issue 6, Pages 439-447Publisher
WILEY
DOI: 10.1002/hup.1143
Keywords
adverse events; antipsychotic agents; observational; quality of life; schizophrenia
Funding
- Eli Lilly and Company
- Organon
- Novartis
- Eli Lilly Australia Pty Ltd, Australia
- Eli Lilly (Eli Lilly and Company, Indianapolis, USA)
Ask authors/readers for more resources
Objective To explore the relative association of adverse events with health-related quality of life (HRQL) in patients (N = 16 091) with schizophrenia, treated with antipsychotic medication. Methods In this post hoc analysis of data from two 3-year observational studies, a mixed effects model with repeated measures was used to evaluate the association between HRQL (EuroQoL visual analogue scale (EQ-VAS)) and pre-specified covariates including: severity of illness, extrapyramidal symptoms, tardive dyskinesia, sexual dysfunction, and clinically significant weight gain (>7% increase from baseline after >= 3 months of treatment). Results Mean EQ-VAS increased from 47.8 +/- 21.7 at baseline to 72.4 +/- 18.4 after 36 months. The rank order of the negative association of adverse events with HRQL was: sexual dysfunction (effect estimate -4.04; 95% CI -4.30 to -3.79), extrapyramidal symptoms (effect estimate -2.09; 95% CI -2.43 to -1.75), and tardive dyskinesia (effect estimate -0.89; 95% CI -1.46 to -0.32). Conclusions Differences were observed in the direction and magnitude of the association between each adverse event and HRQL. Recognition of the relative association of adverse events with HRQL may contribute to improved adherence of patients with schizophrenia to antipsychotic therapy. Copyright (C) 2010 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available